Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

(2018) F Pietrantonio et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer–Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA

(2017) Xin Yang et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

(2017) Filippo Pietrantonio et al.   JNCI-Journal of the National Cancer Institute

A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome

(2017) Tomer Adar et al.   MODERN PATHOLOGY

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

(2017) Filippo Pietrantonio et al.   JNCI-Journal of the National Cancer Institute

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

(2017) Xiaoxing Lv et al.   Jove-Journal of Visualized Experiments

MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas

(2016) Lama Farchoukh et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

(2016) E. Yakirevich et al.   CLINICAL CANCER RESEARCH

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

(2016) Marios Giannakis et al.   Cell Reports

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

(2015) Alessio Amatu et al.   BRITISH JOURNAL OF CANCER

Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma

(2015) Laurent Créancier et al.   CANCER LETTERS

The distribution ofBRAFgene fusions in solid tumors and response to targeted therapy

(2015) Jeffrey S. Ross et al.   INTERNATIONAL JOURNAL OF CANCER

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

(2015) Andrea Sartore-Bianchi et al.   JNCI-Journal of the National Cancer Institute

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

(2015) Enzo Medico et al.   Nature Communications

Identification and characterization of RET fusions in advanced colorectal cancer

(2015) Anne-France Le Rolle et al.   Oncotarget

ALK and ROS1 Overexpression is Very Rare in Colorectal Adenocarcinoma

(2015) Michelle Houang et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

(2015) Andrea Sartore-Bianchi et al.   JNCI-Journal of the National Cancer Institute

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

(2014) Elena Ardini et al.   Molecular Oncology

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

Risk of Cancer in Cases of Suspected Lynch Syndrome Without Germline Mutation

(2013) María Rodríguez–Soler et al.   GASTROENTEROLOGY

Lynch syndrome–associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach

(2013) Douglas J. Hartman et al.   HUMAN PATHOLOGY

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Correlation of tumour BRAF mutations andMLH1methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification

(2012) Michael T Parsons et al.   JOURNAL OF MEDICAL GENETICS

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

Microsatellite Instability in Colorectal Cancer

(2010) C. Richard Boland et al.   GASTROENTEROLOGY

Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening

(2008) J. N. Poynter et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY